Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Daratumumab +/- Cyclophosphamide in R/R Multiple Myeloma
NCT03184194Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2018
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in multiple myeloma (MM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall Response Rate at 5 years. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03184194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184194.